buyModerate cluster of 4
Vida Ventures GP III, L.L.C. bought $5.0M of LBRX
owner at LB PHARMACEUTICALS INC. 333,333 shares at an average of $15.00, traded Sep 12, 2025, filed Sep 16, 2025.
Conviction score
57Value
$5.0M
333,333 shares
Holdings after
2,029
+61% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$5.0M at market
- +10Relative to holdingsHoldings up 61%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-204935, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 12, 2025 | CConversion Common Stockindirect: By Vida Ventures III, L.P. | +547,648 | - | - | 547,648 | Sep 16, 2025 |
| Sep 12, 2025 | CConversion Common Stockindirect: By Vida Ventures III-A, L.P. | +1,262 | - | - | 1,262 | Sep 16, 2025 |
| Sep 12, 2025 | POpen-market purchase Common Stockindirect: By Vida Ventures III, L.P. | +332,566 | $15.00 | $5.0M | 880,214 | Sep 16, 2025 |
| Sep 12, 2025 | POpen-market purchase Common Stockindirect: By Vida Ventures III-A, L.P. | +767 | $15.00 | $12k | 2,029 | Sep 16, 2025 |
| Sep 12, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Vida Ventures III, L.P. | -13,302,666 | $0.00 | $0 | 0 | Sep 16, 2025 |
| Sep 12, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Vida Ventures III-A, L.P. | -30,667 | $0.00 | $0 | 0 | Sep 16, 2025 |
Related signals
Other insiders at LB PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | LB PHARMACEUTICALS INC | Deep Track Biotechnology Master Fund, Ltd. owner | $40M 2,666,666 shares | +389% | |
| 65Notable | LB PHARMACEUTICALS INC | Ran Nussbaum director | $15M 1,000,000 shares | +243% | |
| 57Moderate | LB PHARMACEUTICALS INC | Pontifax Management 4 G.P. (2015) Ltd. owner | $15M 1,000,000 shares | +243% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.